NCT07129161View on ClinicalTrials.gov

Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2027

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

4 cycles(Iparomlimab and Tuvonralimab 5mg/kg) + 2 cycles (Platinum-based doublet chemotherapy)

Iparomlimab and Tuvonralimab 5mg/kg：5mg/kg，q3W Platinum-based doublet chemotherapy：q3w

DRUG

4 cycles(Iparomlimab and Tuvonralimab 5mg/kg) + 4 cycles (Platinum-based doublet chemotherapy)

Iparomlimab and Tuvonralimab 5mg/kg：5mg/kg，q3W Platinum-based doublet chemotherapy：q3w

Trial Locations (2)

Unknown

Sun Yat-sen University Cancer Center, Guangzhou

The Second Affiliated Hospital of Air Force Medical University, Xi'an

All Listed Sponsors
lead

Sun Yat-sen University

OTHER